Senior Research and Development Engineer - Sustaining
About the job
- A bachelor's degree in engineering or a related discipline and a minimum of 5 years of related experience in the medical device or related regulated industry, or an equivalent combination of education and work experience.
- Experience developing product design from concept through regulatory marketing approval.
- Knowledge of statistical analysis software such as Minitab and computer-aided design software such as SolidWorks or Pro/ENGINEER.
- Ability to complete projects individually and as part of a team, exercising judgment within defined procedures and practices.
- Lead and support the design and ongoing life-cycle management of endovascular products through design development, verification and validation, and manufacturability assessments.
- Deliver ideation and prototyping, establish requirements and specifications, and verify design inputs and outputs.
- Serve as a technical team member or lead projects based on value improvement, line extensions, and compliance for commercialized products.
- Respond to technical field inquiries and perform root-cause investigations on product failures.
- Establish and tune detailed requirements, product specifications, and appropriate test methods through competitive testing, literature review, and key opinion leader engagement.
- Refine designs in response to market and customer feedback.
- Collaborate cross-functionally to support development and commercialization of the product platform, facilitate user training, and create required supporting materials.
- Identify, establish, and maintain partnerships with original equipment manufacturer component suppliers, manufacturing partners, and testing vendors as project requirements dictate.
- Experience in endovascular or neurovascular techniques and devices.
About the company
Imperative Care develops medical technologies for stroke and vascular diseases, delivering devices and solutions to healthcare providers to improve patient care. Its approach centers on rapid development and testing, guided by clinical evidence and feedback from physicians, including large multicenter trials like the Imperative Trial. The company moves from concept to market by conducting clinical research and refining products through physician input, with revenue generated from selling devices to hospitals and clinicians. Its differentiator is the combination of evidence-based development, physician-driven insights, and an agile response to the evolving needs of stroke care. The overarching goal is to improve outcomes for stroke patients by providing practical, clinically validated tools that healthcare teams can adopt quickly and effectively.
Company Size
201-500
Company Stage
N/A
Total Funding
$598M
Headquarters
Campbell, California
Founded
2015
Get referred to Imperative Care
See people who can refer or advise you
Simplify's Take
What believers are saying
- March 17, 2026 financing raised $100 million for commercialization and Telos development.
- June 18, 2026 SYMPHONY-PE analysis strengthened its pulmonary embolism franchise.
- May 14, 2026 hiring of Jay Martin added commercial discipline for scaling sales.
What critics are saying
- FDA's Class I recall of ZOOM 71 for catheter fracture still haunts the brand.
- Inari Medical's PTAB fights continue, with IPR2025-01025 instituted December 11, 2025.
- Telos remains unapproved, so Imperative Care depends on clinical wins before 2027.
What makes Imperative Care unique
- Imperative Care owns the Zoom Stroke System, launched with Ikon 24 Pro on July 16, 2026.
- The company pairs stroke devices with Telos, an endovascular robot built for remote procedures.
- Its ADAPT 2.0 study spans up to 750 patients across 50 U.S. sites.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Health Savings Account/Flexible Spending Account
Life Insurance
Disability Insurance
Mental Health Support
Paid Vacation
Paid Sick Leave
Paid Holidays
Parental Leave
Company Equity
Professional Development Budget
Growth & Insights and Company News
6 month growth
2%1 year growth
2%2 year growth
0%Imperative Care has launched the Ikon 24 Pro Guidewire, a neurovascular guidewire designed to improve vascular access during stroke procedures. The device features a uniform 0.024-inch diameter throughout its length, a progressive support profile matched to Zoom Catheters, and enhanced tactile feedback for precise control. The guidewire is engineered to work with Imperative Care's Zoom Stroke System, which includes various catheters designed for clot removal in acute ischemic stroke patients. The system's asymmetric tip design provides 15% greater clot engagement area compared to traditional flat-tip catheters. Dr Kunal Vakharia from the University of South Florida, amongst the first physicians to use the device, noted its reliable balance of support and flexibility, stating it made stroke procedures more efficient. Imperative Care, based in Campbell, California, focuses on advancing treatments for thromboembolic disease.
Imperative Care Launches Ikon 24 Pro Guidewire, Enhancing the Zoom Stroke System to Support More Efficient Stroke Procedures More in Neuro: CAMPBELL, Calif.-(BUSINESS WIRE)-Imperative Care launches Ikon 24 Pro Guidewire, enhancing the Zoom Stroke System to support more efficient stroke procedures. See full post here as originally published on this site
Imperative Care, a medical technology company focused on thromboembolic disease treatments, has appointed Jay Martin as Chief Commercial Officer. Martin will lead commercial strategy, expand strategic partnerships and build infrastructure to support the company's growth and commercialisation efforts. Martin brings over 25 years of executive leadership experience in medical devices, robotics and imaging. Most recently, he served as President of VulcanForms, where he helped build a backlog exceeding $1 billion in 18 months. He previously spent eight years at Globus Medical, serving as President of Imaging, Navigation and Robotics, and was part of the leadership team that grew the company from approximately $400 million to over $2 billion in revenue. The Campbell, California-based company develops treatments for patients suffering from blood clot formation in veins and arteries.
Imperative Care, Inc., a medical technology company focused on advancing treatments for patients suffering from thromboembolic disease, today announced the
Imperative Care, a medical technology company treating thromboembolic disease, has closed an oversubscribed $100 million convertible note financing. The round was co-led by new investors Elevage Medical Technologies and Perceptive Advisors, alongside existing investor Catalio Capital Management. New investors Longaeva Partners and Brown Advisory participated, with support from existing backers including Ally Bridge Group and Bain Capital Life Sciences. Evan Melrose, CEO of Elevage Medical Technologies, has joined Imperative Care's board of directors. The funding will support commercialisation of the company's stroke and vascular thrombectomy portfolios, next-generation product development including the Telos robotic platform, and clinical evidence generation. Imperative Care's products have been used in over 78,000 procedures commercially. BofA Securities and J.P. Morgan served as joint placement agents.